MN
MediciNova, Inc.
MNOV · NASDAQ
$3.30 +4.10% (+$0.13)
1M +116.99%
Market Cap $162.4M
P/E Ratio -
Div. Yield -
ROE 26.51%
Bulios Fair Price
$2.2
33.3% downside
Current Price
$3.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MNOV is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
23 /100
Expensive P/S 176.46x
P/B 4.36x
P/E N/A
Growth
0 /100
Declining Book val. growth 16.03%
EPS growth N/A
Rev. growth N/A
Profitability
17 /100
Weak Gross margin 42.39%
Net margin 1,168.20%
Op. margin 1,287.41%
Quality
0 /100
Poor ROIC 31.54%
ROE 26.51%
ROA 26.59%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 8.75x
Int. coverage N/A
Stability
59 /100
Moderate Beta 0.63x
EPS volatility 38.57%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MNOV
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yuichi Iwaki
Employees
6
Headquarters
La Jolla
Upcoming events
12 NOV
Earnings
Upcoming earnings report